China News Service, Chongqing, May 9th (Han Lu and Wang Xueyu) On the 9th, sponsored by the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology, and jointly undertaken by the Hematology Oncology Center of the Affiliated Tumor Hospital of Chongqing University and the Chongqing Public Health Center for immunodeficiency related diseases in the central and western regions The inaugural meeting of the Lymphoma Diagnosis and Treatment Cooperation Group was held in Chongqing.
On the same day, more than 30 experts dedicated to the treatment of hematological tumors and HIV infection in seven provinces and one city in the central and western regions established the central and western HIV-related lymphoma diagnosis and treatment collaboration group.
It is understood that with the promotion of the country's "Four Frees and One Care" policy and the combined use of highly effective antiretroviral drugs, the chance of HIV-infected persons dying from opportunistic infections is decreasing year by year, and their survival period is close to that of HIV-negative people.
However, due to the massive destruction of immune cells in the body of advanced AIDS patients, the immunity is reduced, and the probability of suffering from various opportunistic infections and malignant tumors also increases.
Liu Yao, director of the Hematology Oncology Center of the Cancer Hospital of Chongqing University, said that among HIV patients with tumors, the incidence of lymphoma not only surpassed Kaposi's sarcoma and ranked first, but also one of the main causes of death.
"The clinical manifestations of HIV-related lymphoma patients are similar to those of ordinary lymphoma patients. The treatment of HIV-infected malignant lymphoma is consistent with the treatment principles of non-HIV-infected people." Liu Yao introduced that the only difference is HIV-infected patients/ AIDS patients also need to take antiviral drugs at the same time as anti-tumor treatment to restore immune function and ensure the smooth progress of anti-tumor treatment.
It is reported that at present, a considerable proportion of patients are diagnosed with lymphoma and HIV infection is found at the same time. Most patients are not optimistic about the prospects for treatment of HIV combined with lymphoma and are unwilling to actively seek medical treatment, leading to delays in treatment.
Liu Yao said that this is actually a misunderstanding of patients. “As long as patients with HIV-infected lymphoma start standardized treatment including autologous hematopoietic stem cell transplantation as soon as possible, they can get a long-term chance of survival.”
The reporter learned that the Affiliated Tumor Hospital of Chongqing University has so far treated 86 HIV-related lymphoma patients and accumulated relevant clinical diagnosis and treatment experience and case data.
In order to further expand the number of admissions and improve the effectiveness of diagnosis and treatment, the Hematology Oncology Center of the Cancer Hospital of Chongqing University, under the framework of the CSCO China Anti-Lymphoma Alliance, has united with more than 30 experts dedicated to the treatment of hematological tumors and HIV infection in seven provinces and one city in the central and western regions. A collaborative group for the diagnosis and treatment of HIV-related lymphoma in the Midwest was established.
Liu Yao said that after the establishment of the collaboration group, a collaboration mechanism between medical institutions will be established to improve the diagnosis and treatment capabilities of regional HIV infection-related lymphomas, promote the advancement of admission and treatment, and actively develop new technologies to benefit a wider range of related patients.